Bank of America Increases Eli Lilly and Company (NYSE:LLY) Price Target to $1,294.00

Eli Lilly and Company (NYSE:LLY) had its price objective lifted by stock analysts at Bank of America from $1,293.00 to $1,294.00 in a report issued on Thursday,Benzinga reports. The firm presently has a “buy” rating on the stock. Bank of America‘s price objective would indicate a potential upside of 35.43% from the company’s previous close.

Several other research firms have also recently commented on LLY. Loop Capital set a $1,200.00 price target on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Scotiabank restated an “outperform” rating and issued a $1,300.00 target price on shares of Eli Lilly and Company in a research note on Thursday, February 5th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and set a $1,285.00 price target on shares of Eli Lilly and Company in a research note on Friday, March 6th. Wolfe Research boosted their price target on Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an “outperform” rating in a research note on Wednesday, December 3rd. Finally, HSBC lowered shares of Eli Lilly and Company from a “hold” rating to a “reduce” rating and cut their price objective for the company from $1,070.00 to $850.00 in a research report on Tuesday, March 17th. Two research analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $1,222.22.

Eli Lilly and Company Stock Up 3.9%

NYSE:LLY opened at $955.45 on Thursday. The business’s fifty day moving average price is $999.28 and its 200 day moving average price is $966.87. The firm has a market capitalization of $902.73 billion, a price-to-earnings ratio of 41.63, a PEG ratio of 1.07 and a beta of 0.51. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95.

Eli Lilly and Company (NYSE:LLY) last issued its earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating analysts’ consensus estimates of $7.48 by $0.06. The company had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a return on equity of 102.94% and a net margin of 31.66%.The firm’s quarterly revenue was up 42.6% on a year-over-year basis. During the same quarter in the prior year, the company earned $5.32 EPS. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. On average, sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eli Lilly and Company

A number of large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Eli Lilly and Company by 1.2% in the 4th quarter. Vanguard Group Inc. now owns 81,965,974 shares of the company’s stock worth $88,087,193,000 after acquiring an additional 1,006,885 shares during the period. State Street Corp increased its stake in shares of Eli Lilly and Company by 1.8% in the fourth quarter. State Street Corp now owns 35,361,916 shares of the company’s stock worth $38,002,744,000 after purchasing an additional 635,358 shares during the period. Capital Research Global Investors lifted its position in shares of Eli Lilly and Company by 20.9% during the 3rd quarter. Capital Research Global Investors now owns 25,088,371 shares of the company’s stock worth $19,141,787,000 after purchasing an additional 4,332,008 shares during the last quarter. Morgan Stanley boosted its stake in Eli Lilly and Company by 2.7% during the 4th quarter. Morgan Stanley now owns 15,593,019 shares of the company’s stock valued at $16,757,510,000 after purchasing an additional 407,166 shares during the period. Finally, Capital World Investors grew its holdings in Eli Lilly and Company by 0.4% in the 4th quarter. Capital World Investors now owns 15,031,750 shares of the company’s stock valued at $16,154,619,000 after buying an additional 61,851 shares during the last quarter. Institutional investors own 82.53% of the company’s stock.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: FDA approves Foundayo (orforglipron), Lilly’s once?daily oral GLP?1 for obesity — expands the company’s weight?loss franchise with an easy?to?scale pill that the company plans to sell via LillyDirect (low advertised self?pay price and payer coverage could accelerate adoption). Lilly’s weight-loss pill wins US approval (Reuters)
• Positive Sentiment: Lilly agreed to buy Centessa (initial ~$6.3B, up to ~$7.8B with milestones), broadening into sleep?wake and narcolepsy assets — strategic diversification that reduces reliance on GLP?1 revenue and bolsters mid?term growth optionality. Eli Lilly to Buy Centessa (CNBC)
• Positive Sentiment: Unusually large call?option volume and targeted bullish trades around LLY indicate investor enthusiasm and short?term upside conviction following the FDA approval and M&A news. This derivatives activity can amplify near?term price moves. Options Traders Pick Up Pharma Stock After Eli Lilly Buyout (Yahoo)
• Neutral Sentiment: Competitive dynamics: Novo Nordisk is responding (subscription pricing, product tweaks) and remains a formidable rival in GLP?1s — Foundayo’s approval intensifies the duel but outcomes depend on clinical preference, pricing, and payer decisions. Wegovy vs. Foundayo (TipRanks)
• Negative Sentiment: Policy risk: Lilly’s CEO publicly opposed codifying the Trump administration’s Most Favored Nations drug?pricing deals into law — signals potential tension with government pricing initiatives that could affect future pricing/reimbursement. Lilly opposes MFN codification (CNBC)
• Negative Sentiment: Deal scrutiny: a law firm has opened an investor probe into the Centessa sale price/process — potential legal or shareholder hurdles could slow closing or create contingencies tied to the transaction. Centessa investor alert (BusinessWire)

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.